freeze-thaw comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Dapagliflozin/metformin, sold under the brand name Xigduo Xr among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and metformin and is taken by mouth. Dapagliflozin/metformin was approved for use in the European Union in January 2014, in the United States in February 2014, and in Australia in July 2014.
. This analysis shows that the end product of a linear, irreversible reaction network has an isotopic composition determined solely by the composition of the starting material and the KIE of the first reaction in the network.
In veterinary anesthesia, ketamine is often used for its anesthetic and analgesic effects on cats, dogs, rabbits, rats, and other small animals. It is frequently used in induction and anesthetic maintenance in horses. It is an important part of the "rodent cocktail", a mixture of drugs used for anesthetising rodents. Veterinarians often use ketamine with sedative drugs to produce balanced anesthesia and analgesia, and as a constant-rate infusion to help prevent pain wind-up. Ketamine is also used to manage pain among large animals. It is the primary intravenous anesthetic agent used in equine surgery, often in conjunction with detomidine and thiopental, or sometimes guaifenesin. Ketamine appears not to produce sedation or anesthesia in snails. Instead, it appears to have an excitatory effect.
Sources: en.wikipedia.org
== Excavation and preparation == Usually the first evidence of fossil dinosaur eggs to be discovered are shell fragments that have eroded away from the original eggs and been transported downhill by the elements. If the source eggs can be found the area must be examined for more unexposed eggs. If the paleontologists are fortunate enough to have found a nest, the number and arrangement of the eggs must be estimated. Excavation must proceed to significant depth since many dinosaur nests include multiple layers of eggs. As the underside of the nest is excavated, it would be covered by material like newspaper, tin foil, or tissue. Afterwards, the entire block is covered in multiple layers of plaster-soaked strips of burlap. When the plaster is dried, the block is undercut the rest of the way and turned over. The fine work of cleaning the egg fossils is performed in a laboratory. Preparation usually begins from the underside of the block, which tends to be the best preserved. Because of their fragility, cleaning fossil eggs requires patience and skill. Scientists use delicate instruments like dental picks, needles, small pneumatic engraving tools, and X-Acto knives. Scientists must determine at what point to stop cleaning based on their own criteria. If eggs are fully extracted they can be more fully studied individually at the cost of information regarding the spatial relationships between eggs or if the eggs had hatched.
While Stalin's death in 1953 slightly relaxed tensions, the situation in Europe remained an uneasy armed truce. The Soviets, who had already created a network of mutual assistance treaties in the Eastern Bloc by 1949, established a formal alliance therein, the Warsaw Pact, in 1955. It stood opposed to NATO.
== The "no waste" culture == Sake kasu can be considered as a part of the "no waste" culture in Japan. Sake kasu is the waste produced by sake production, and the Japanese decided to use it because they do not want to waste any of the ingredients. A lot of sake kasu is produced during sake production and a lot of sake kasu is considered as industrial waste and being discarded. In order to reduce the waste produced by the sake kasu in Japan, it is recycled for use in other products. Some breweries sell their sake kasu directly to restaurants or put it into packages sold in convenient stores and supermarkets.
=== New books === Thomas Charles - Geiriadur Ysgrythyrol Theophilus Jones - History of the County of Brecknock, vol. 1 Titus Lewis - A Welsh — English Dictionary, Geiriadur Cymraeg a Saesneg Robert Southey - Madoc
Sources: en.wikipedia.org
== Early life and career == Kennedy was born in Centreville, Mississippi, and raised in Zachary, Louisiana. He graduated from Zachary High School as co-valedictorian in 1969. He then attended Vanderbilt University, where he majored in philosophy, political science, and economics. He graduated in 1973 with a Bachelor of Arts, magna cum laude, and was elected president of his class and to Phi Beta Kappa. Kennedy received a Juris Doctor degree in 1977 from the University of Virginia School of Law. There, he was an executive editor of the Virginia Law Review and, graduating in the top ten percent of his class, he was elected to the Order of the Coif. In 1979, he earned a Bachelor of Civil Law, an advanced degree, with first class honours from Oxford University, where he was a member of Magdalen College and studied under Rupert Cross and J. H. C. Morris. Kennedy was a partner in the New Orleans and Baton Rouge law firm Chaffe McCall from 1985 to 1987 and 1992 to 1996. He also served as an adjunct professor at Louisiana State University's Paul M. Hebert Law Center in Baton Rouge from 2002 to 2016.
The Selous Scouts also sought to increase the divisions between the ZANLA and ZIPRA by posing as members of one group and then attacking members of the other group. These tactics became publicly known and embarrassed the government. The Selous Scouts were probably responsible for killing black business owners in rural areas who provided support for the insurgents. These killings were conducted secretly. Special Branch provided the Selous Scouts with poisoned clothing, food, beverages and medicines that the unit inserted into the guerrilla supply chains. The use of contaminated supplies resulted in the reported deaths of over 800 guerrillas, and the likely death toll probably reached well over 1,000. The Rhodesian Directorate of Military Intelligence estimated in 1978 that the Selous Scouts were responsible for 68% of insurgent fatalities within Rhodesia. These casualties largely resulted from attacks by Rhodesian Army units on insurgents located by the Selous Scouts. However, the unit's ruthless tactics were counter-productive as they contributed to further alienating Rhodesia's black population from the government. This formed part of broader flaws in the Rhodesian counter-insurgency strategy, and the historian Jakkie Cilliers has written that "the Selous Scouts were merely the instruments of an overly aggressive and punitive strategy, simply directed at killing as many insurgents as possible and punishing the rural black population to force them to desist from support for the insurgent forces. The apparent success of the Selous Scouts led to the unit being glamorised.
Small amounts of organoselenium compounds have been used to modify the catalysts used for the vulcanization for the production of rubber. Selenium is used in some anti-dandruff shampoos in the form of selenium disulfide such as Selsun and Vichy Dereos brands.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.